Skip to main content

Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus

As of 25th October 2021, dapagliflozin 5mg is no longer authorised for the treatment of people with type 1 diabetes mellitus (T1DM) and should no longer be used in this population . This is based on AstraZeneca’s decision to remove the Type 1 diabetes indication for dapagliflozin 5mg.

ABCD are disappointed that the use of dapaglifozin has been withdrawn for people with type 1 diabetes. 

This is not due to any safety concern for dapagliflozin in any indication, including people with type 1 diabetes.

Factors associated with the difference in HbA1c and FreeStyle Libre Glucose management indicator (GMI) in patients with type 1 diabetes

Priya Sarkar1, Manushri Jain1,2, Tejas Kalaria2, Brett Healey1, Rajeev Raghavan1, Rousseau Gama2

1 Diabetes and Endocrinology, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton WV10 0QP

2 Clinical Biochemistry, New Cross Hospital, Black Country Pathology Services, Royal Wolverhampton NHS Trust, Wolverhampton WV10 0QP